Abstract
Spirulina platensis was first isolated from Lake Texcoco by Aztecs in the sixteenth century. In 2012, spirulina was considered to be safe dietary supplement by the Food and Drug Administration (FDA). Spirulina is a cyanophytic microalgae that is often considered as single cell protein. It contains many essential amino acids, proteins, fatty acids, antioxidant pigments, carotenoids, and cyanogenic pigments, that is, phycocyanobilins and phycocyanins (Eriksen, Appl Microbiol Biotechnol, 80(1):1–4, 2008). Components of spirulina are investigated for many health benefits and for pharmaceutical uses (Karkos et al., Spirulina in clinical practice: evidence-based human applications). Spirulina has been found to have a role in growth, immunity (Wu et al., Arch Toxicol, 90(8):1817–40, 2016), antioxidant (Wu et al., Arch Toxicol, 90(8):1817–40, 2016), antiviral (Ayehunie et al., J Acquir Immune Defic Syndr Hum Retrovirol, 18(1):7–12, 1998), antitoxicologic, anti-cancerogenic (Hirahashi et al., Int Immunopharmacol, 2(4):423–34, 2002), antidiabetic (Layam and Reddy, Diabetol Croat, 35(2):29–33, 2006), and neuroprotective properties. In this study, we focused on spirulina components in anti-Parkinson’s and anti-Alzheimer’s activity. Four potential targets, two for each activity, that is, structure of parkinE3 ligase (PDB ID:4I1H) and structure of BACE bound to 5-(3-(5-chloropyridin-3-yl)phenyl)-5-cyclopropyl-2-imino-3-methylimidazolidin-4one (PDBI D:4DJx) for anti-Parkinson’s activity and structure of human MAO B in complex with selective inhibitor safinamide (PDB ID:2V5Z) and crystal structure of human BACE-1 in complex with CNP520(PDB ID:6EQM) for anti-Alzheimer’s activity, have been selected. The in silico results and scoring of virtual screening, that is, molecular docking, were compared with commonly used marketed drugs such as levodopa for Parkinson’s disease (PD) and rivastigmine (Rösler et al., BMJ, 318(7184):633–40, 1999) for Alzheimer’s disease.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Eriksen NT. Production of phycocyanin—a pigment with applications in biology, biotechnology, foods and medicine. Applied microbiology and biotechnology. 2008 Aug;80(1):1–4.
Karkos PD, Leong SC, Karkos CD, Sivaji N, Assimakopoulos DA. Spirulina in clinical practice: evidence-based human applications.
Wu Q, Liu L, Miron A, Klímová B, Wan D, Kuča K. The antioxidant, immunomodulatory, and anti-inflammatory activities of Spirulina: an overview. Archives of toxicology. 2016 Aug;90(8):1817–40.
Ayehunie S, Belay A, Baba TW, Ruprecht RM. Inhibition of HIV-1 replication by an aqueous extract of Spirulina platensis (Arthrospira platensis). Journal of acquired immune deficiency syndromes and human retrovirology: official publication of the International Retrovirology Association. 1998 May 1;18(1):7–12.
Hirahashi T, Matsumoto M, Hazeki K, Saeki Y, Ui M, Seya T. Activation of the human innate immune system by Spirulina: augmentation of interferon production and NK cytotoxicity by oral administration of hot water extract of Spirulina platensis. International Immunopharmacology. 2002 Mar 1;2(4):423–34.
Layam A, Reddy CL. Antidiabetic property of spirulina. Diabetologia croatica. 2006;35(2):29–33.
Rösler M, Bayer T, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, Stähelin HB, Hartman R, Gharabawi M. Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trial Commentary: Another piece of the Alzheimer’s jigsaw. Bmj. 1999 Mar 6;318(7184):633–40.
Kovacs GG. Current concepts of neurodegenerative diseases. Emj Neurol. 2014 Jul;1:78–86.
Thanvi BR, Lo TC. Long term motor complications of levodopa: clinical features, mechanisms, and management strategies. Postgraduate medical journal. 2004 Aug 1;80(946):452–8.
Choi WY, Kang DH, Lee HY. Effect of fermented Spirulina maxima extract on cognitive-enhancing activities in mice with scopolamine-induced dementia. Evidence-Based Complementary and Alternative Medicine. 2018 Jan 1;2018.
Angeles DC, Ho P, Dymock BW, Lim KL, Zhou ZD, Tan EK. Antioxidants inhibit neuronal toxicity in Parkinson’s disease-linked LRRK 2. Annals of clinical and translational neurology. 2016 Apr;3(4):288–94.
Venugopal C, Demos CM, Jagannatha Rao KS, Pappolla MA, Sambamurti K. Beta-secretase: structure, function, and evolution. CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders). 2008 Jun 1;7(3):278–94.
Luo YC, Jing P. Molecular Interaction of Protein-Pigment C-Phycocyanin with Bovine Serum Albumin in a Gomphosis Structure Inhibiting Amyloid Formation. International journal of molecular sciences. 2020 Jan;21(21):8207.
Gupta E, Gupta SR, Kumar A, Kulshreshtha A, Ranjan R, Kumar N. Molecular Docking Study to Identify Potent Inhibitors of Alpha-synuclein Aggregation of Parkinson’s Disease.
Acknowledgments
This work was supported by the Institute of Pharmaceutical Technology, Sri Padmavati Mahila Visvavidyalayam, Tirupati.
Conflict of Interest
Conflict of interest declared none.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this paper
Cite this paper
Sara, L., Thanmayee, R., Satyakavya, P.V., Avulapati, T., Swathi, K. (2023). Screening of Spirulina Components for Anti-Parkinson’s and Anti-Alzheimer’s Activity by in Silico Methods and Docking Studies. In: Vlamos, P. (eds) GeNeDis 2022. GeNeDis 2022. Advances in Experimental Medicine and Biology, vol 1423. Springer, Cham. https://doi.org/10.1007/978-3-031-31978-5_13
Download citation
DOI: https://doi.org/10.1007/978-3-031-31978-5_13
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-31977-8
Online ISBN: 978-3-031-31978-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)